Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Moberg Pharma AB ( (SE:MOB) ).
Moberg Pharma AB has formed a Nomination Committee ahead of its Annual General Meeting for the fiscal year 2025. The committee, comprising representatives from the company’s largest shareholders and the Chairman of the Board, will propose the election of the Chairman of the Board, board composition, and auditors’ fees. This move is part of the company’s governance process to ensure shareholder representation and strategic alignment.
More about Moberg Pharma AB
Moberg Pharma AB is a Swedish pharmaceutical company that specializes in commercializing proprietary innovations based on drug delivery of proven compounds. The company’s flagship product, MOB-015, is a novel topical treatment for onychomycosis, with market approval in 13 EU countries and sales in Sweden and Norway under the brand name Terclara. Moberg Pharma is headquartered in Stockholm and is listed on Nasdaq Stockholm under Small Cap.
Average Trading Volume: 101,242
Current Market Cap: SEK371.6M
For detailed information about MOB stock, go to TipRanks’ Stock Analysis page.